Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 242 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Visual Acuity Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

NCT04995341
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Investigational ultracompact OCT and OCTA system, retinal photographs
Device
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Visual Field Analysis With Artificial Intelligence

NCT06920290
View directory record Official record
Conditions
Glaucoma, Visual Field Defect
Interventions
Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence
Device
Lead sponsor
Sight Intelligence Engineering Corporation
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 18, 2026, 3:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

NCT06891885
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

NCT06349759
View directory record Official record
Conditions
Mesopic Vision, Night Vision Loss
Interventions
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, Placebo
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
25
States / cities
Pheonix, Arizona • Scottsdale, Arizona • Bakersfield, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational

Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)

NCT02420132
View directory record Official record
Conditions
Macular Edema, Macular Degeneration
Interventions
Ranibizumab
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 18, 2026, 3:55 AM EDT
Not yet recruiting Not applicable Interventional

TearCare in Young Adults

NCT07579156
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
TearCare®
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Terminated Not applicable Interventional

Macugen for Histoplasmosis

NCT00272766
View directory record Official record
Conditions
Ocular Histoplasmosis, Choroidal Neovascularization
Interventions
pegaptanib sodium
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2006 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational

Natural History of the Progression of X-Linked Retinitis Pigmentosa

NCT04926129
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
Other: Assessments
Other
Lead sponsor
NightstaRx Ltd, a Biogen Company
Other
Eligibility
7 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 18, 2026, 3:55 AM EDT
Terminated Not applicable Interventional

Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Granular Corneal Dystrophy

NCT06202651
View directory record Official record
Conditions
Granular Dystrophy, Corneal
Interventions
Nd:YAG Laser
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 18, 2026, 3:55 AM EDT
Not listed Not applicable Interventional

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

NCT01581151
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 18, 2026, 3:55 AM EDT
Active, not recruiting No phase listed Observational

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F

NCT04765345
View directory record Official record
Conditions
Retinal Degeneration, Retinitis Pigmentosa, Eye Diseases, Hereditary
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 3:55 AM EDT
Recruiting Not applicable Interventional

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

NCT05438732
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
smaller incision, new generation implantable miniature telescope (SING-IMT)
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
65 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Loma Linda, California • Long Beach, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 18, 2026, 3:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients

NCT06064916
View directory record Official record
Conditions
Pseudophakia
Interventions
Visual Acuity, Defocus Curve, Intraocular Lens Satisfaction (IOLSAT) Questionnaire, Quality of Vision After Surgery (QUVID) Questionnaire, Visual Disturbance Questionnaire, Topography and Tomography
Diagnostic Test · Other
Lead sponsor
Berkeley Eye Center
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intraocular Steroid After Cataract Surgery Study

NCT00478764
View directory record Official record
Conditions
Cataract
Interventions
intraocular triamcinolone and gatifloxicin
Drug
Lead sponsor
Dean Health System
Other
Eligibility
40 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baraboo, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2007 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 4 Interventional

Comparison of Postoperative Visual Acuity and Spectacle Independence Between the Tecnis Multifocal Intraoculer Lens (IOL) and the Crystalens Accommodating IOL

NCT01275118
View directory record Official record
Conditions
Cataract
Interventions
Tecnis Multifocal IOL, crystalens Accommodating IOL
Device
Lead sponsor
Mark Packer, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 18, 2026, 3:55 AM EDT
Not listed Phase 2Phase 3 Interventional

The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity

NCT02260973
View directory record Official record
Conditions
Cataract, Dry Eye Disease
Interventions
Omega-3 (Triglyceride form)
Dietary Supplement
Lead sponsor
Physician Recommended Nutriceuticals
Industry
Eligibility
30 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

NCT00306488
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration, AMD
Interventions
OT-551 antioxidant eye drop
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 18, 2026, 3:55 AM EDT
Not listed Not applicable Interventional

Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+

NCT06574646
View directory record Official record
Conditions
Cataract
Interventions
LAL+, Clareon Vivity Toric IOL
Device
Lead sponsor
The Eye Associates
Other
Eligibility
45 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 18, 2026, 3:55 AM EDT
Terminated Phase 1 Interventional

Dichoptic Virtual Reality Therapy for Amblyopia in Adults

NCT02246556
View directory record Official record
Conditions
Amblyopia, Anisometropia, Strabismus
Interventions
Dichoptic therapy, Patching therapy, Dioptic (non-dichoptic) therapy
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Phase 2 Interventional Results available

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

NCT01526889
View directory record Official record
Conditions
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions
LFG316, Conventional Therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Golden, Colorado • Marietta, Georgia • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Not applicable Interventional Results available

Long Term Follow-up of the VisAbility™ Micro Insert System for Presbyopic Patients

NCT03811249
View directory record Official record
Conditions
Presbyopia
Interventions
VisAbility™ Micro Insert
Device
Lead sponsor
VisDura, Inc.
Industry
Eligibility
45 Years to 60 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Orange, California • San Diego, California • Honolulu, Hawaii + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 18, 2026, 3:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of the PresVIEW Implant for the Improvement of Near Vision in Patients With Presbyopia

NCT01166568
View directory record Official record
Conditions
Presbyopia
Interventions
PresVIEW Scleral Implants
Device
Lead sponsor
VisDura, Inc.
Industry
Eligibility
50 Years to 60 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
14
States / cities
Beverly Hills, California • San Diego, California • Des Plaines, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 18, 2026, 3:55 AM EDT